Update to UNOLS Considerations for Conducting Seagoing Science

The following information and guidance is provided as an update and adjustment to previous UNOLS Guidance related to conducting science onboard U.S. Academic Research Fleet vessels (see: 1June2020 UNOLS COVID-19 Considerations For Conducting Seagoing Science, 11May2021 Update to UNOLS COVID-19 Guidance, and 4June2021 Update to UNOLS Considerations for Conducting Seagoing Science). Those elements of the previous UNOLS Guidance not addressed in the following paragraphs remain in effect.

This update has been developed with advice and guidance provided by George Washington Medical Faculty Associates.

Based on the below stated (see “Background”) observations, recommendations, guidelines and published data, the following changes are made to previously issued UNOLS guidelines for consideration in conducting oceanographic research on U.S. Academic Research Fleet vessels. In all cases, the Vessel Operators and Chief Scientists can choose to use stricter protocols if deemed appropriate for any reason.

**UPDATED GUIDANCE**

**Our goal is that all persons aboard Academic Research Fleet vessels are fully vaccinated against COVID-19. Due to the close quarters of vessel operations, we recommend that operating institutions mandate vaccinations for all cruise participants.** UNOLS expects that all involved parties will maximize efforts to ensure that all persons (crew and science party) are fully vaccinated\(^1\) by a ship’s sail date. In addition to ensuring that all persons are fully vaccinated, the pre-travel safety, symptom-checking and testing protocols addressed in Table 1 should be implemented.

Any requests to proceed without a fully vaccinated vessel will require concurrence from the funding agency, institution and UNOLS prior to proceeding. Risk level shall be determined through the established Risk Mitigation Process. Any unvaccinated participant is expected to complete a strict 10-day quarantine that will end on the day of embarkation and must have a negative PCR test that is obtained no more than 48 hours prior to the day of embarkation. For ships that have voyages that are longer than 7 days and/or anticipate being more than 24-hour sail from medical facilities, consideration should be given to having on-board NAAT or Ag testing.

If a vessel must proceed with one or more unvaccinated persons, additional testing and safety measures will need to be implemented for those persons as addressed in Table 2. In addition, the Operator and Chief Scientist should consider the following precautions:

1. Operating the ship within 2 days of adequate medical facilities.
2. Obtaining the informed consent of other crew/science party.
3. Outfitting the vessel with the ability to conduct on-board NAAT or Ag testing.
4. The cost associated with quarantining requirements for those who voluntarily do not get vaccinated, aside from medical or religious accommodations, must be supported by the individual or the institution.
Update to UNOLS Considerations for Conducting Seagoing Science

Table 1 – Fully Vaccinated Persons

<table>
<thead>
<tr>
<th>Action Required</th>
<th>At least 14 days prior to travel</th>
<th>At least 7 days prior to travel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submit COVID-19 Vaccination Documentation</td>
<td></td>
<td>Begin Pre-travel safety measures:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Avoid all crowded public spaces</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Mask in all crowded outdoor spaces</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Mask in all indoor public spaces</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Mask in indoor private spaces (e.g. home) if there are unvaccinated (e.g. young children) and/or immunocompromised persons in the same household</td>
</tr>
<tr>
<td></td>
<td></td>
<td>At least 7 days prior to travel</td>
</tr>
<tr>
<td>Begin daily symptom tracking</td>
<td></td>
<td>Begin daily symptom tracking</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• If develop symptoms of possible COVID-19, initiate quarantine and obtain RT-PCR test. There should be at least 48 hours between this test and the pre-travel test</td>
</tr>
<tr>
<td>1-3 days prior to embarkation</td>
<td>RT-PCR Testing</td>
<td>RT-PCR or Ag test on embarkation</td>
</tr>
<tr>
<td></td>
<td>Tests should be as close as possible to travel date.</td>
<td>Tests should be as close as possible to embarkation.</td>
</tr>
<tr>
<td>Upon embarkation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2 – Persons Not Fully Vaccinated

<table>
<thead>
<tr>
<th>Action Required</th>
<th>15-17 days prior to embarkation</th>
<th>14 days prior to embarkation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete RT-PCR</td>
<td></td>
<td>Submit any COVID-19 vaccination documentation</td>
</tr>
<tr>
<td>14 days prior to embarkation</td>
<td>1. Begin pre-quarantine safety measures:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Avoid crowded indoor public spaces</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mask in all indoor public spaces</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mask in all indoor private spaces (e.g. home) if there are unvaccinated (e.g. young children) and/or immunocompromised persons in the same household</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Begin daily symptom tracking.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• If develop symptoms of possible COVID-19, initiate quarantine and obtain RT-PCR test. There should be at least 48 hours between this test and the pre-travel test</td>
<td></td>
</tr>
<tr>
<td>10 days before embarkation</td>
<td>Begin Pre-embarkation quarantine</td>
<td></td>
</tr>
<tr>
<td>~2 days prior to embarkation</td>
<td>PCR or Ag test</td>
<td>Tests should be as close as possible to embarkation date.</td>
</tr>
</tbody>
</table>

Key:
1. A person is considered fully vaccinated 14 days after completing a full vaccine series. (1 shot of J&J, 2 shots for all other series). A person who qualifies for a “booster” vaccine dose should consult with their physician regarding the necessity of such additional doses
2. Travel begins when a person leaves their last place of residence to join the vessel.
3. Public is defined as an event or space with more than one household

Vers: 1.7-25 Aug 2021
Update to UNOLS Considerations for Conducting Seagoing Science

4. Private is defined as occurring in and including only persons from one’s own household
5. CDC COVID-19 symptoms
7. Ag: any CDC recognized Antigen test.
8. This includes incomplete series (e.g. one vaccine of a 2-shot series) or vaccination with a vaccine that has not had FDA or WHO approval (EUA/EUL)
9. Quarantine: For purposes of this document, only persons not fully vaccinated against COVID-19 are expected to complete pre-embarkation quarantine (unless quarantine is instituted by another health authority- for e.g. as a result of contact tracing efforts). During the quarantine period, persons are expected to establish single-occupancy residence and to take their meals in their residence.
10. If a person has a positive PCR (or any NAAT) or Ag test they will not be allowed to sail (or board a vessel). Before being allowed to board, they must be cleared by a physician. Unless they are recently recovered from COVID-19, they will need to complete a period of ISOLATION before they are allowed to sail. The necessity of repeating the testing (for e.g. documenting a negative Ag test) will be left to physician discretion. Currently, documenting a negative PCR test is not considered an alternative to isolation and is not needed to provide clearance once isolation is completed.

Risk levels shall be determined through the established Risk Mitigation Process. Any requests to proceed without quarantine for high risk cruises require concurrence from the funding agency, institution and UNOLS prior to proceeding. In all cases, current or more strict protocols can be utilized in cases where risk levels are determined to be significant.

When determining risk: Considerations in determining risk should include distance from shore, cruise duration, investment, science party size, whether public transport travel is required, the number of high-risk participants, the ratio of vaccinated to unvaccinated persons.

Travel Recommendations – for crew and science party who travel to meet the ship
- Travel to port should be conducted in private vehicle when possible.
- Travelers should always wear a mask and minimize interaction during travel.

Background

Vaccinations
Persons who have been fully vaccinated against COVID-19 can be infected with the virus. Despite becoming infected, they are much more likely to have subclinical (asymptomatic) illness. Such persons, despite being vaccinated and asymptomatic can transmit COVID-19 to others.

A small percentage of vaccinated persons who become infected will manifest clinical illness (breakthrough cases) and have the following repercussions to becoming infected:
- Manifest any signs of infection
- Become seriously ill and/or need hospitalization
Update to UNOLS Considerations for Conducting Seagoing Science

- Die from COVID-19 complications.
- Transmit COVID-19 to others

The potential for true vaccine failure (being vaccinated but not mount an adequate immune response) is low in the general population. In the populations with increased rates of vaccine failure (e.g., persons with cancer, recipients of organ transplants, etc.), the CDC currently recommends a 3rd vaccine dose. Recommendations for an additional dose of J&J have not been released.


Vaccines
Currently one vaccine is fully approved by the U.S. Food & Drug Administration.
  - Pfizer-BioNTech vaccination: 2 doses

Two vaccines are authorized under an Emergency Use Authorization (EUA) by the U.S. Food & Drug Administration (FDA):
  - Moderna COVID-19 vaccination: 2 doses
  - Johnson & Johnson – Janssen COVID-19 vaccination: 1 dose

On August 18, 2021 HHS issued a press release outlining plans to offer booster doses to immunocompetent persons who have been fully vaccinated. Details on the rollout of these vaccines are pending and for now, persons who are 14 days out from completing the above regimen will be considered fully vaccinated. Booster doses are not anticipated to be offered before the week of September 20, 2021.

Update to UNOLS Considerations for Conducting Seagoing Science

In addition to the above 2 vaccines, the WHO has given EUL approval to:
  o Astra Zeneca: 2 doses
  o Sinopharm
  o Sinovac

- Published data indicates that all FDA/WHO EUA/EUL vaccines are safe and effective, but surveillance for effectiveness and adverse events continues.
- Moderna petitioned the FDA for full approval in early June 2021.

U.S. Vaccination Status
As of August 25, vaccinated data:
  • Total Population
    o ~52% are fully vaccinated
    o ~61% are partially vaccinated

Globally over four billion vaccine doses have been administered but overall vaccine availability and vaccination rates remain low in most countries.

US Infection and Death Rates in U.S. by 7-Day Moving Average

<table>
<thead>
<tr>
<th>Date</th>
<th>Cases/day</th>
<th>Deaths/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan 8, 2021</td>
<td>~252,000</td>
<td>3,364</td>
</tr>
<tr>
<td>Feb 8, 2021</td>
<td>~107,000</td>
<td>2,488</td>
</tr>
<tr>
<td>Mar 8, 2021</td>
<td>55,000</td>
<td>1,246</td>
</tr>
<tr>
<td>Apr 8, 2021</td>
<td>63,000</td>
<td>601</td>
</tr>
<tr>
<td>May 8, 2021</td>
<td>40,000</td>
<td>579</td>
</tr>
<tr>
<td>May 22, 2021</td>
<td>24,000</td>
<td>504</td>
</tr>
<tr>
<td>June 22, 2021</td>
<td>12,000</td>
<td>252</td>
</tr>
<tr>
<td>July 22, 2021</td>
<td>48,000</td>
<td>254</td>
</tr>
<tr>
<td>Aug 25, 2021</td>
<td>141,000</td>
<td>775</td>
</tr>
</tbody>
</table>


UNOLS calls attention to the following:
1. The fact that the CDC’s current recommendations for all persons (vaccinated and unvaccinated) are INTERIM, and amendments are therefore expected.
2. The CDC makes explicit that these recommendations are subject to local governmental laws/regulations; business/workplace guidance.
3. The continued increase in vaccinations in the U.S is expected but no clear number has been set to define “herd immunity” or adequate to “return to normal”.
4. The continued variability in vaccination rates and disease transmission rates at a state,
county, and community level within in the U.S.

5. A ship can be considered a congregate setting with colocation of living accommodations, eating facilities and work areas.

6. A ship represents a potential remote location without ready access to adequate healthcare facilities.

7. Operating a ship during COVID-19 without instituting strict pre-cruise quarantine and testing protocols even when community vaccination rates are high and disease transmission rates are low introduces a finite chance of active, symptomatic COVID-19 disease with potential onboard transmission.

8. The chance of on-board disease and transmission increases with a greater proportion of persons who are vaccine non-responders and if not fully vaccinated persons have boarded.

A person is fully vaccinated only if:

1. More than 14 days have lapsed after vaccination series has been completed.
2. Vaccination was with an FDA or WHO EUA/EUL approved vaccine.
3. Appropriate documentation (CDC card, government or healthcare program sponsored documentation) including electronic documentation is presented.
4. Documentation of full vaccination has been verified.